Hims & Hers Health Stock Tumbles Amid Visa Concerns and FTC Lawsuit

Hims & Hers Health's stock price has plummeted by 7.21% over the past week, sparking concern among investors about the company's high-growth story.

The decline follows a wave of negative headlines, including a Bloomberg report that Visa had placed Hims & Hers Health in its Acquirer Monitoring Program due to unusually high credit card disputes in its weight-loss subscriptions.

The Federal Trade Commission (FTC) is also suing the company for deceptive billing and difficult cancellations, which has further exacerbated concerns about its subscription model's compliance costs.

Barclays has cut its price target for Hims & Hers Health, signaling a more cautious view on the company's risk profile and future earnings power.